• Explore /
  • Poster
  • / Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.

Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer.

Abstract Poster

Authors

null

Lawrence G. Lum

University of Virginia, Charlottesville, VA

Lawrence G. Lum , Archana Thakur , Zaid S. Al-Kadhimi , Abhinav Deol , Michael S. Simon , Dana Schalk , Qin Liu , Lawrence E. Flaherty

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Other Breast Cancer Subtypes

Clinical Trial Registration Number

NCT 01022138

Citation

J Clin Oncol 37, 2019 (suppl; abstr 1080)

DOI

10.1200/JCO.2019.37.15_suppl.1080

Abstract #

1080

Poster Bd #

161

Abstract Disclosures

Similar Posters

First Author: Deepa Bai Jagtap

Poster

2014 ASCO Annual Meeting

Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.

Long-term follow up for a phase I trial HER2/neu-targeted T cells in women with advanced breast cancer.

First Author: Lawrence G. Lum

First Author: Martin Wermke

First Author: Dean F. Bajorin